Company Name: Thermo Fisher Scientific Inc.

Problem of the Company: As per my analysis, the significant level of indebtedness is the serious problem of Thermo Fisher Scientific Inc.

It can be removed through debt equity ratio analysis and analysis of financial leverages. The company should reduce its various overhead costs to increase the profit. The debt payment must be done on a priority basis. The advances from market can be used to pay the unpaid amount of various stakeholders. Multiple sources of income or business must be identified to achieve for success in payment of in debt.

Revenue Analysis of Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. (Thermo Fisher Scientific or 'the company') recorded revenues of $16,889.6 million during FY2014, an increase of 29% over FY2013. In FY2014, the US, the company's largest geographic market, accounted for 48.2% of the total revenues.

The company generates revenues through four business segments: laboratory products and services (38% of the total revenues, excluding eliminations, in FY2014), life sciences solutions (24.1%), specialty diagnostics (19.2%), and analytical instruments (18.7%).

Revenue by segment

In FY2014, the laboratory products and services segment recorded revenues of $6,601.5 million, an increase of 3.2% over FY2013.

The life sciences solutions segment recorded revenues of $4,195.7 million in FY2014, as compared to $712.5 million in FY2013.

The specialty diagnostics segment recorded revenues of $3,343.6 million in FY2014, an increase of 4.8% over FY2013.

The analytical instruments segment recorded revenues of $3,252.2 million in FY2014, an increase of 3.1% over FY2013.

Revenue by geography

The US, Thermo Fisher Scientific's largest geographic market, accounted for 48.2% of the total revenues in FY2014. Revenues from the US reached $8,147.7 million in FY2014, an increase of 23.1% over FY2013.

China accounted for 7.2% of the total revenues in FY2014. Revenues from China reached $1,223.1 million in FY2014, an increase of 36.4% over FY2013.

Germany accounted for 6% of the total revenues in FY2014. Revenues from Germany reached $1,005.9 million in FY2014, an increase of 32.6% over FY2013.

The UK accounted for 4.5% of the total revenues in FY2014. Revenues from the UK reached $754.5 million in FY2014, an increase of 41.7% over FY2013.

Other countries accounted for 34.1% of the total revenues in FY2014. Revenues from other countries reached $5,758.4 million in FY2014, an increase of 34.4% over FY2013.

Compettor of Thermo Fisher Scientific Inc.

Revenue Analysis of Becton, Dickinson and Company

The company recorded revenues of $10,282 million during FY2015, an increase of 21.7% over FY2014.

In FY2015, the US, the company's largest geographic market, accounted for 49.3% of the total revenues.

The company generates revenues through two business segments: medical (62.8% of the total revenues in FY2015) and life sciences (37.2%).

Revenues by segment

In FY2015, the medical segment recorded revenues of $6,460 million, an increase of 41.3% over

FY2014.

The life sciences segment recorded revenues of $3,822 million in FY2015, a decrease of 1.3% compared to FY2014.

Revenues by geography

The US, BDs largest geographic market, accounted for 49.3% of the total revenues in FY2015. Revenues from the US reached $5,069 million in FY2015, an increase of 48.3% over FY2014.

Europe accounted for 23.7% of the total revenues in FY2015. Revenues from Europe reached $2,434 million in FY2015, an increase of 2.1% over FY2014.

Greater Asia accounted for 15% of the total revenues in FY2015. Revenues from Greater Asia reached $1,545 million in FY2015, an increase of 7.5% over FY2014.

Other regions accounted for 12% of the total revenues in FY2015. Revenues from other regions reached $1,234 million in FY2015, an increase of 2% over FY2014.

By using the revenue analysis of Thermo Fisher Scientific Inc. and its competitor Becton Dickinson, I want the quantitative analysis calculation part for the serious problem of indebtedness, which Thermo Fisher Scientific Inc. is facing. I need a clear explanation please.